Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822663 | 0.87 | PDPK1 (0.35) | PDPK1AURKAAURKB | |
| SCHEMBL4822483 | 0.87 | PDPK1 (0.37) | PDPK1AURKAAURKBNR2E3ITK | |
| SCHEMBL4829089 | 0.86 | SYK (0.39) | AURKAAURKBITK | |
| SCHEMBL4829230 | 0.86 | KMT2A (0.36) | AURKAAURKB | |
| SCHEMBL4830717 | 0.86 | KMT2A (0.36) | AURKAAURKB | |
| SCHEMBL4824819 | 0.83 | AURKA (0.54) | PDPK1AURKAAURKBNR2E3 | |
| SCHEMBL4822495 | 0.81 | AURKA (0.38) | AURKAAURKB | |
| SCHEMBL4829476 | 0.79 | AURKA (0.41) | AURKAAURKBITK | |
| SCHEMBL4829256 | 0.78 | AURKA (0.38) | PDPK1AURKAAURKBNR2E3ITK | |
| SCHEMBL4830751 | 0.77 | AURKA (0.43) | PDPK1AURKAAURKBNR2E3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235065-A1 | Aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-10-19 | — | — | US | claimed |
| US-7462639-B2 | e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060235065-A1 | Aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235065-A1 | Aminopyrazole derivatives | CYP3A43, CYP3A5, CYP3A4 | PDPK1 676/4885AURKA 742/4885AURKB 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.